NEWS HIGHLIGHTS
Published Studies Related to Humulin (Insulin Injection)
Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. [2009.11]
OBJECTIVES: The objective of this analysis was to determine the cost-effectiveness of exenatide vs. insulin glargine in patients with type 2 diabetes failing to achieve glycaemic control with oral antidiabetic agents, in the German setting, from a third-party payer perspective... CONCLUSIONS: Exenatide was projected to be associated with similar clinical outcomes and increased costs compared with insulin glargine. Analysis of cost-effectiveness from a third-party perspective suggests that exenatide is likely to represent good value for money in the German setting.
Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. [2009.10.12]
Abstract Objectives: To assess the efficacy and safety of biphasic insulin aspart 70/30 (BIAsp 30) and insulin glargine, administered once daily in subjects with type 2 diabetes inadequately controlled with oral anti-diabetic drugs. Research design and methods: In this 26-week, open-labeled, randomized, parallel-group, multinational, treat-to-target trial, 480 insulin-naive subjects were randomized to receive either BIAsp 30 before dinner or insulin glargine at bedtime, both in combination with metformin and glimepiride.
A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. [2009.10]
PURPOSE: An optimal target for glucose control in ICU patients remains unclear. This prospective randomized controlled trial compared the effects on ICU mortality of intensive insulin therapy (IIT) with an intermediate glucose control... CONCLUSIONS: In this prematurely stopped and therefore underpowered study, there was a lack of clinical benefit of intensive insulin therapy (target 4.4-6.1 mmol/L), associated with an increased incidence of hypoglycaemia, as compared to a 7.8-10.0 mmol/L target. (ClinicalTrials.gov # NCT00107601, EUDRA-CT Number: 200400391440).
Effects of acute administration of acylated and unacylated ghrelin on glucose and insulin concentrations in morbidly obese subjects without overt diabetes. [2009.10]
OBJECTIVE: To investigate the effects of unacylated ghrelin (UAG) and co-administration of acylated ghrelin (AG) and UAG in morbid obesity, a condition characterized by insulin resistance and low GH levels... CONCLUSION: Co-administration of AG and UAG as a single i.v. bolus injection causes a significant decrease in insulin concentration in non-diabetic subjects suffering from morbid obesity. Since glucose concentration did not change in the first hour after Comb administration, our data suggest a strong improvement in insulin sensitivity. These findings warrant studies in which UAG with or without AG is administered for a longer period of time. Administration of a single bolus injection of UAG did not influence glucose and insulin metabolism.
Randomized trial on the effects of a 7-d low glycemic diet and exercise intervention on insulin resistance in older obese humans. [2009.09.30]
BACKGROUND: The optimal combination of diet and exercise that produces the greatest reversal of obesity-related insulin resistance is unknown. OBJECTIVES: We examined the effects of a combined 7-d low-glycemic index (low-GI) diet and exercise training intervention on insulin sensitivity in older obese humans... CONCLUSIONS: These findings suggest that the metabolic improvements after short-term exercise training in older obese individuals are dependent on increased physical activity and are not influenced by a low-GI diet. However, a low-GI diet has added benefit in alleviating hypertension, thus reducing the risk of diabetic and vascular complications.
Clinical Trials Related to Humulin (Insulin Injection)
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes [Completed]
This will be a randomized, open label, parallel group, multicenter study. There will be two
phases in the study. Phase 1 (Baseline to Week 24) will compare the efficacy and safety of
regimens of basal insulin intensified with either Symlin or rapid acting insulin in patients
with type 2 diabetes who have either been on a prior regimen of insulin for less than 6
months and were taking less than 50 U total of insulin per day OR are candidates for the
initiation of insulin therapy. The purpose of Phase 2 (Week 24 to Week 36) is to explore
further intensification of diabetes regimens in patients failing to achieve HbA1c <=6. 5% at
Week 24.
Comparison of Insulins Aspart and Lispro in Insulin Pumps [Active, not recruiting]
The purpose of the study is to study compare the glycemic control between insulins aspart and
lispro 48 to 100 hours after pump infusion line change in subjects with type 1 using diabetes
using an insulin pump.
Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2) [Completed]
The purpose of this study is to test for superiority in improvements from baseline in patient
reported outcomes in subjects with type 1 or type 2 diabetes when treated with insulin
glargine plus rapid acting insulin glulisine MDI versus treatment with premix insulin.
Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes [Active, not recruiting]
This trial is conducted in Europe.
The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood
glucose levels) of insulin detemir, insulin aspart and biphasic insulin aspart 30, when added
to current OAD treatment in type 2 diabetes and to verify the safety of use ( number and
severity of episodes of hypoglycaemia, body weight and side effects).
Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes [Completed]
This trial is conducted in Europe and the United States of America (USA).
The purpose of this study is to test whether insulin detemir is a safe and at least as
effective alternative to insulin glargine for the control of blood glucose in basal/bolus
therapy in patients with type I diabetes.
|
